410 related articles for article (PubMed ID: 18089682)
21. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
Wang J; Hu W; Xie H; Zhang H; Chen H; Zeng C; Liu Z; Li L
Lupus; 2007; 16(9):707-12. PubMed ID: 17728363
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.
Lanata CM; Mahmood T; Fine DM; Petri M
Lupus; 2010 Jul; 19(8):935-40. PubMed ID: 20388722
[TBL] [Abstract][Full Text] [Related]
23. Sequential therapies for proliferative lupus nephritis.
Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
[TBL] [Abstract][Full Text] [Related]
24. Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis.
Tang KT; Tseng CH; Hsieh TY; Chen DY
Int J Rheum Dis; 2018 Jun; 21(6):1163-1172. PubMed ID: 29879319
[TBL] [Abstract][Full Text] [Related]
25. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
26. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
27. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients.
Pisoni CN; Sanchez FJ; Karim Y; Cuadrado MJ; D'Cruz DP; Abbs IC; Khamasta MA; Hughes GR
J Rheumatol; 2005 Jun; 32(6):1047-52. PubMed ID: 15940766
[TBL] [Abstract][Full Text] [Related]
28. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
Chan TM; Tse KC; Tang CS; Mok MY; Li FK;
J Am Soc Nephrol; 2005 Apr; 16(4):1076-84. PubMed ID: 15728784
[TBL] [Abstract][Full Text] [Related]
29. Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis.
Kazderova M; Jancova E; Rysava R; Merta M; Tesar V
Arch Med Res; 2008 Jan; 39(1):115-9. PubMed ID: 18068004
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis.
Aragon E; Resontoc LP; Chan YH; Lau YW; Tan PH; Loh HL; Ng KH; Yap HK
Lupus; 2016 Apr; 25(4):399-406. PubMed ID: 26537422
[TBL] [Abstract][Full Text] [Related]
31. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
Dooley MA; Jayne D; Ginzler EM; Isenberg D; Olsen NJ; Wofsy D; Eitner F; Appel GB; Contreras G; Lisk L; Solomons N;
N Engl J Med; 2011 Nov; 365(20):1886-95. PubMed ID: 22087680
[TBL] [Abstract][Full Text] [Related]
32. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study.
Walsh M; Solomons N; Lisk L; Jayne DR
Am J Kidney Dis; 2013 May; 61(5):710-5. PubMed ID: 23375819
[TBL] [Abstract][Full Text] [Related]
33. Effects of mycophenolate mofetil for patients with crescentic lupus nephritis.
Tang Z; Yang G; Yu C; Yu Y; Wang J; Hu W; Zeng C; Chen H; Liu Z; Li L
Nephrology (Carlton); 2008 Dec; 13(8):702-7. PubMed ID: 18771470
[TBL] [Abstract][Full Text] [Related]
34. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB
N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.
Ikeuchi H; Hiromura K; Takahashi S; Mishima K; Sakurai N; Sakairi T; Kaneko Y; Maeshima A; Kuroiwa T; Nojima Y
Mod Rheumatol; 2014 Jul; 24(4):618-25. PubMed ID: 24252014
[TBL] [Abstract][Full Text] [Related]
36. Clinical presentation and outcomes of childhood-onset membranous lupus nephritis.
Pereira M; Muscal E; Eldin K; Hicks MJ; Sagcal-Gironella ACP; DeGuzman M; Wenderfer SE
Pediatr Nephrol; 2017 Dec; 32(12):2283-2291. PubMed ID: 28717937
[TBL] [Abstract][Full Text] [Related]
37. Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia.
Almalki AH; Alrowaie FA; Alhozali HM; Almalki NK; Alsubei AI; Alturki MS; Sadagah LF
Lupus; 2019 Aug; 28(9):1082-1090. PubMed ID: 31296138
[TBL] [Abstract][Full Text] [Related]
38. Mycophenolate mofetil for remission induction in severe lupus nephritis.
Cross J; Dwomoa A; Andrews P; Burns A; Gordon C; Main J; Mathieson P; O'Donoghue D; Jayne D;
Nephron Clin Pract; 2005; 100(3):c92-100. PubMed ID: 15824513
[TBL] [Abstract][Full Text] [Related]
39. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
Dall'Era M; Stone D; Levesque V; Cisternas M; Wofsy D
Arthritis Care Res (Hoboken); 2011 Mar; 63(3):351-7. PubMed ID: 21080348
[TBL] [Abstract][Full Text] [Related]
40. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies.
Sahin GM; Sahin S; Kantarci G; Ergin H
Nephrology (Carlton); 2007 Jun; 12(3):285-8. PubMed ID: 17498124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
